Survey of Ophthalmology
Volume 54, Issue 6 , Pages 663-670, November 2009

Plus Disease

  • Bradley V. Davitt, MD

      Affiliations

    • Departments of Ophthalmology and Pediatrics, Cardinal Glennon Children's Medical Center, Saint Louis University School of Medicine, St. Louis, Missouri, USA
    • Corresponding Author InformationReprint address: Bradley V. Davitt, MD, Cardinal Glennon Children's Medical Center, 1465 South Grand Boulevard, St. Louis, MO 63104.
  • ,
  • David K. Wallace, MD, MPH

      Affiliations

    • Departments of Ophthalmology and Pediatrics, Duke University School of Medicine, Durham, North Carolina, USA

published online 10 August 2009.

Abstract 

Our understanding of plus disease as an important sign for severe retinopathy of prematurity (ROP) has gradually been refined over the past 30 years. As a result of the Early Treatment for ROP (ETROP) randomized trial, the presence of plus disease is now the primary indication for laser treatment. Since the Cryotherapy for ROP trial first introduced a standard photograph as the minimum abnormality necessary for diagnosing plus disease, an intermediate level of vascular dilatation and tortuosity (pre-plus disease) has been defined. However, the recognition of plus disease remains problematic, primarily because of its subjective nature. As our understanding of the pathologic basis for plus disease in ROP grows, objective methods of recognizing and measuring retinal vascular abnormalities are also being designed. Semiautomated methods are being developed to quantify the vascular morphologic changes seen in plus disease and show promise for augmenting clinical judgment in the recognition and timely treatment of ROP.

Key words: ETROP, ICROP, plus disease, prematurity, pre-plus disease, retinopathy, ROPtool, threshold

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The authors reported no proprietary or commercial interest in any product mentioned or concept discussed in this article. Supported by an unrestricted grant from Research to Prevent Blindness, Inc., New York, New York, USA.

PII: S0039-6257(09)00066-6

doi:10.1016/j.survophthal.2009.02.021

Survey of Ophthalmology
Volume 54, Issue 6 , Pages 663-670, November 2009